Metabolites, low-molecular weight organic molecules, are a constant product of living biological systems. Unlike genes, metabolites are temporally dynamic, changing as an organism or cell population lives, feeds, ages and develops disease. The comprehensive analysis of metabolites in a system, or metabolomics, can provide a deep and incredibly insightful picture of a living system.
Within the metabolome of living systems, microbiota play a significant role. Recent scientific studies reveal that well over 99% of life on our planet is microbial. This microbial “dark matter” is enormous and found not only within us (the human microbiome) but all around us. With no teeth, scales, traditional nervous systems or immunity, these organisms rely exclusively on complex metabolites to communicate, mediate their environments and even control their hosts. This ancient, highly evolved, and diverse chemical language is a vastly untapped source of new disease insights and potential starting points for new medicines.
Computational Metabolomics for “Natural Product” Drug Discovery
From aspirin, to penicillin, to rapamycin, the natural world has been, and continues to be, a prolific source of medically relevant chemical starting points for groundbreaking therapeutics. Unfortunately, typical approaches in this field are plagued by long-timelines and sample complexity.
Since 2012, Sirenas has been the pioneer and global leader in harnessing computational metabolomics for the discovery of small molecule therapeutic leads from natural sources. Our approach, dubbed ATLANTIS™, unleashes cutting-edge computational algorithms on large, proprietary metabolomic and bioassay datasets to rapidly uncover key chemical and biological insights for the small molecules present in complex samples from extremely biodiverse environments. The end result: the ability to mine a vastly untapped chemical language for new scaffolds effective across a broad array of high value targets disease models.
Computational Metabolomics for Human-based Drug Discovery
Building on the technology and approaches from ATLANTIS™, GALILEO™ merges large human and mammalian metabolomic data sets with modern computational and machine-learning approaches to reveal key biological insights associated with human health and disease. Our goal is to uncover new therapeutic targets and biomarkers of disease and aging, as well as key bioactive metabolites that may be used as novel chemical scaffolds.
We seek to deploy both ATLANTIS™ and GALILEO™ in the discovery of transformative medicines.
In February 2018, Sirenas and Bristol-Meyers Squibb entered into a multi-target collaboration to deploy ATLANTIS™ against certain undisclosed challenging therapeutic targets to identify potential drug candidates. https://www.bms.com/
Since 2016, Sirenas has received two research grant awards from the Bill & Melinda Gates Foundation totaling $1.68 M. These funds will accelerate the use of ATLANTIS™, including the integration of machine learning approaches, to identify therapeutic candidates to treat widespread infectious diseases including tuberculosis and malaria. https://www.gatesfoundation.org/
Sirenas partnered with Calibr, a not-for-profit translational research organization, in October 2016 to identify therapeutic candidates in disease areas including immunology, oncology, and neglected disease. http://calibr.org/
If you would like to seek a partnership opportunity with Sirenas, contact firstname.lastname@example.org
What the world is buzzing about Sirenas
Sirenas Enters Into Multi-Target Collaboration With Bristol-Myers Squibb. View press release.
Sirenas receives research grant totaling $1.68 M to accelerate its drug discovery technology, ATLANTIS™. View press release.
Sirenas establishes world leading Scientific Advisory Board. View press release.
Sirenas appoints industry leaders to its Board. View press release.
CEO and Founder Eduardo Esquenazi shares “The Secret Language of Life” at TEDxUCSD. Watch the full TED talk.
HATCH by San Diego Magazine captures the story of Founder and CEO Eduardo Esquenazi and how it shaped Sirenas. Read full article.
Founder and CEO Eduardo Esquenazi speaks with the Smithsonian about his journey and the path forward for Sirenas LLC. Read full interview.
Learn more about how Sirenas is meeting the challenges of natural product discovery in a feature by Fast Company’s Fast Co.Exist!
Sirenas and Calibr form a drug discovery collaboration. View press release.
Sirenas is a panel finalist for South by Southwest 2017! Alongside Fabien Cousteau, Sirenas CEO Eduardo Esquenazi will address “Racing Climate Change to Cure Neglected Diseases” – Read full panel description.
CEO Eduardo Esquenazi speaks with Xconomy about Sirenas’ key innovation. Learn more.
Sirenas is awarded a grant to identify nature-inspired drug leads for neglected diseases. View press release.
The San Diego Business Journal features Sirenas in the wake of grant announcement. Read more.
On this week’s BioTech Nation, looking for new drugs … in the ocean. Dr. Eduardo Esquenazi, Founder and CEO of Sirenas LLC, talks about bioprospecting. Listen to full podcast.
3550 General Atomics Court. Suite 02/211
San Diego, CA 92121
email: email@example.com / ph 858-909-5685
Sirenas creates and connects large scale metabolomic data with cutting-edge technology and algorithms to efficiently yield breakthrough medical discoveries. We are actively looking for talented individuals to join our innovative team.email firstname.lastname@example.org